China
Africa
Explore chapters and articles related to this topic
Polycystic Ovarian Syndrome (PCOS)
Published in Charles Theisler, Adjuvant Medical Care, 2023
Myo-Inositol: Therapy that combined myo-inositol (MI) and D-chiro-inositol (DCI) was tested in young overweight women affected by polycystic ovary syndrome (PCOS).5 Twenty-one women received MI plus DCI combined treatment at the ratio of 40:1 (the physiologic ratio of the two isomers in the body) in soft gel capsule containing 550 mg of MI, 13.8 mg of DCI, and 200 μg of folic acid twice a day.5
Gestational Diabetes
Published in Vincenzo Berghella, Maternal-Fetal Evidence Based Guidelines, 2022
A. Dhanya Mackeen, Richard S. Vigh, Kajal Angras
Myo-inositol has also been shown to be safe and effective in preventing GDM. Myo-inositol (2 g b.i.d.) decreases insulin resistance [65] and reduces the incidence of GDM in both high-risk and low-risk patient populations [59, 66]. Of the types of stereoisomers, myo-inositol has demonstrated the most benefit compared to D-chiro-inositol [67]. Furthermore, myo-inositol supplementation started in the first trimester has been shown to reduce the risk of preterm delivery and macrosomia in patients who are at high-risk for GDM [66, 68].
Postimplantation diabetic embryopathy
Published in Moshe Hod, Lois G. Jovanovic, Gian Carlo Di Renzo, Alberto de Leiva, Oded Langer, Textbook of Diabetes and Pregnancy, 2018
Ulf J. Eriksson, Parri Wentzel
Rat embryos cultured in inositol-depleted serum develop neural tube defects (NTDs),154 which demonstrates the teratogenic capacity of inositol deficiency. In addition, when curly tail mouse embryos, who have a predisposition for developing folate-resistant NTDs, are cultured in inositol-depleted serum, their NTD rate increases further.155 If the inositol-depleted culture medium is successively supplemented with inositol, the NTD rate in the curly tail embryos decreases proportionally155 and results in a lower NTD rate than in nontreated curly tail embryos.156 Also, administering myo-inositol or d-chiro-inositol to curly tail mice, both in vivo and in vitro, diminishes the NTD/spina bifida rate.157
The efficacy of myo-inositol supplementation to reduce the incidence of gestational diabetes: a meta-analysis
Published in Gynecological Endocrinology, 2022
Myo-inositol, one stereoisomer of inositol, is the most common one [13,38]. It leads to the production of phosphoinositides which have an insulin-like effect on metabolic enzymes in glucose metabolism [39–42]. The efficacy of myo-inositol to prevent gestational diabetes is through improving glucose homeostasis as an insulin sensitizer substance [43–45]. In addition, the α-lactalbumin addition promotes intestinal absorption and bioavailability of myo-inositol [42]. Regarding the sensitivity analysis, significant heterogeneity was found for the incidence of gestational diabetes, and may be caused by several factors. Firstly, the doses of myo-inositol were different among the included RCTs, ranging from 1100 mg to 4000 mg daily. The dose of myo-inositol supplementation was recommended to be 2000 mg myo-inositol twice a day [14,18,25]. Secondly, pregnant women with have different baseline characteristics such as glucose and lipid metabolism, which may affect the efficacy assessment of myo-inositol. Thirdly, myo-inositol is combined with various agents such as D-Chiro inositol, and more studies are needed to find the ideal combination methods of inositol supplementation.
Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study
Published in Gynecological Endocrinology, 2022
Keerthana Rajasekaran, Neena Malhotra, Reeta Mahey, Rajesh Khadgawat, Mani Kalaivani
Each participant was counseled on the pretreatment drug intake and duration before IVF cycle, besides potential side effects. The block randomization with varying size was used to randomize the patients into the treatment groups and the sequentially numbered opaque sealed envelope (SNOSE) technique was used for allocation concealment. To avoid selection bias, 102 women were randomized into 50 (group 1) and 52 (group 2) in each group to receive Myo 2 g bid and Met 850 mg bid respectively, at least 12 weeks prior to IVF cycle. Allocation concealment was possible with the drugs dispensed in opaque plastic bottles bearing the code. Tablets containing only myo-inositol were not available and are dispensed as combinations with folic acid or D-chiro-inositol, therefore similar-looking tablets containing only myo-inositol 2 g were ordered from the pharmacy. Both patients and investigators being blinded to the allocation. The allocation code was broken once the patients initiated the treatment cycle.
Inositols: reflections on how to choose the appropriate one for PCOS
Published in Gynecological Endocrinology, 2020
As a putative solution, with no such side effects, the integrative treatment using inositols was proposed. Inositols are a large family of nine stereoisomers belonging to a sugar alcohol family. Practically, inositols have the same chemical structure of glucose and once entered in the cells they provide the structural basis for inositol phosphates, important secondary messengers and relevant components of the structural lipids phosphatidylinositol and phosphatidylinositol phosphate [5]. Among the nine isomers myo-inositol (MYO) and D-chiro-inositol (DCI) have been demonstrated to have good therapeutic effectiveness in PCOS patients and no side effects [6]. Since the use of both inositols for treating PCOS is quite widespread, a better understanding about this treatment option is needed.